A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

While early steps have been taken in Austria and France, Belgium MEP Yvan Verougstraete stresses the need for a long-term ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

Trofolastat is a prostate-specific membrane antigen-targeting agent cleared for use with Technetium-99m for cancerous lesion ...

After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...

In January, the U.S. Drug Enforcement Administration announced new rules to make permanent expanded telehealth access that ...

CRISPR technology has revolutionised genetic engineering, offering unprecedented precision in DNA editing with vast implications for medicine, agriculture and conservation. Yet, its power demands ...

A new study from Queen Mary University of London found that 9% of all reported adverse drug reactions (ADRs) reported to the UK medicines regulator are associated with medications where side effect ...

Critical Path Institute® and Boston Medical Center published results for six biomarkers that could improve the early and accurate detection of kidney injury, leading to both the development of safer ...

NEW YORK – Invivoscribe announced Thursday that its test for FLT3 mutations in patients with leukemia has achieved regulatory compliance in the UK and Switzerland.